697 related articles for article (PubMed ID: 25703571)
21.
Woo M; Wood C; Kwon D; Park KP; Fejer G; Delorme V
Front Immunol; 2018; 9():438. PubMed ID: 29593716
[TBL] [Abstract][Full Text] [Related]
22. New approaches to tuberculosis--novel drugs based on drug targets related to toll-like receptors in macrophages.
Tomioka H
Curr Pharm Des; 2014; 20(27):4404-17. PubMed ID: 24245765
[TBL] [Abstract][Full Text] [Related]
23. Host factors subverted by
Kalra R; Tiwari D; Dkhar HK; Bhagyaraj E; Kumar R; Bhardwaj A; Gupta P
Int Rev Immunol; 2023; 42(1):43-70. PubMed ID: 34678117
[TBL] [Abstract][Full Text] [Related]
24. Recent updates on drug resistance in Mycobacterium tuberculosis.
Singh R; Dwivedi SP; Gaharwar US; Meena R; Rajamani P; Prasad T
J Appl Microbiol; 2020 Jun; 128(6):1547-1567. PubMed ID: 31595643
[TBL] [Abstract][Full Text] [Related]
25. Repurposing Tamoxifen as Potential Host-Directed Therapeutic for Tuberculosis.
Boland R; Heemskerk MT; Forn-Cuní G; Korbee CJ; Walburg KV; Esselink JJ; Carvalho Dos Santos C; de Waal AM; van der Hoeven DCM; van der Sar E; de Ries AS; Xie J; Spaink HP; van der Vaart M; Haks MC; Meijer AH; Ottenhoff THM
mBio; 2023 Feb; 14(1):e0302422. PubMed ID: 36475748
[TBL] [Abstract][Full Text] [Related]
26. Antituberculous drugs modulate bacterial phagolysosome avoidance and autophagy in Mycobacterium tuberculosis-infected macrophages.
Genestet C; Bernard-Barret F; Hodille E; Ginevra C; Ader F; Goutelle S; Lina G; Dumitrescu O;
Tuberculosis (Edinb); 2018 Jul; 111():67-70. PubMed ID: 30029917
[TBL] [Abstract][Full Text] [Related]
27. From infection niche to therapeutic target: the intracellular lifestyle of
Rankine-Wilson LI; Shapira T; Sao Emani C; Av-Gay Y
Microbiology (Reading); 2021 Apr; 167(4):. PubMed ID: 33826491
[No Abstract] [Full Text] [Related]
28. Something Old, Something New: Ion Channel Blockers as Potential Anti-Tuberculosis Agents.
Mitini-Nkhoma SC; Chimbayo ET; Mzinza DT; Mhango DV; Chirambo AP; Mandalasi C; Lakudzala AE; Tembo DL; Jambo KC; Mwandumba HC
Front Immunol; 2021; 12():665785. PubMed ID: 34248944
[TBL] [Abstract][Full Text] [Related]
29. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic host-directed strategies to improve outcome in tuberculosis.
Young C; Walzl G; Du Plessis N
Mucosal Immunol; 2020 Mar; 13(2):190-204. PubMed ID: 31772320
[TBL] [Abstract][Full Text] [Related]
31. Revisiting hypoxia therapies for tuberculosis.
Oehlers SH
Clin Sci (Lond); 2019 Jun; 133(12):1271-1280. PubMed ID: 31209098
[TBL] [Abstract][Full Text] [Related]
32. Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis.
Zumla A; Rao M; Dodoo E; Maeurer M
BMC Med; 2016 Jun; 14():89. PubMed ID: 27301245
[TBL] [Abstract][Full Text] [Related]
33. Mycobacterium tuberculosis: Surviving and Indulging in an Unwelcoming Host.
Mishra A; Surolia A
IUBMB Life; 2018 Sep; 70(9):917-925. PubMed ID: 30129097
[TBL] [Abstract][Full Text] [Related]
34. All-trans Retinoic Acid Augments Autophagy during Intracellular Bacterial Infection.
Coleman MM; Basdeo SA; Coleman AM; Cheallaigh CN; Peral de Castro C; McLaughlin AM; Dunne PJ; Harris J; Keane J
Am J Respir Cell Mol Biol; 2018 Nov; 59(5):548-556. PubMed ID: 29852080
[TBL] [Abstract][Full Text] [Related]
35. Host-directed therapy to combat mycobacterial infections.
Kilinç G; Saris A; Ottenhoff THM; Haks MC
Immunol Rev; 2021 May; 301(1):62-83. PubMed ID: 33565103
[TBL] [Abstract][Full Text] [Related]
36. Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice.
Koo MS; Manca C; Yang G; O'Brien P; Sung N; Tsenova L; Subbian S; Fallows D; Muller G; Ehrt S; Kaplan G
PLoS One; 2011 Feb; 6(2):e17091. PubMed ID: 21364878
[TBL] [Abstract][Full Text] [Related]
37. Host-Directed Therapies for Tackling Multi-Drug Resistant Tuberculosis: Learning From the Pasteur-Bechamp Debates.
Zumla A; Maeurer M;
Clin Infect Dis; 2015 Nov; 61(9):1432-8. PubMed ID: 26219693
[TBL] [Abstract][Full Text] [Related]
38. Functional Inhibition of Host Histone Deacetylases (HDACs) Enhances
Moreira JD; Koch BEV; van Veen S; Walburg KV; Vrieling F; Mara Pinto Dabés Guimarães T; Meijer AH; Spaink HP; Ottenhoff THM; Haks MC; Heemskerk MT
Front Immunol; 2020; 11():36. PubMed ID: 32117228
[TBL] [Abstract][Full Text] [Related]
39. Improving treatment outcomes for MDR-TB - Novel host-directed therapies and personalised medicine of the future.
Rao M; Ippolito G; Mfinanga S; Ntoumi F; Yeboah-Manu D; Vilaplana C; Zumla A; Maeurer M
Int J Infect Dis; 2019 Mar; 80S():S62-S67. PubMed ID: 30685590
[TBL] [Abstract][Full Text] [Related]
40. HDAC3 inhibitor RGFP966 controls bacterial growth and modulates macrophage signaling during Mycobacterium tuberculosis infection.
Campo M; Heater S; Peterson GJ; Simmons JD; Skerrett SJ; Mayanja-Kizza H; Stein CM; Boom WH; Hawn TR
Tuberculosis (Edinb); 2021 Mar; 127():102062. PubMed ID: 33639591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
